



16477-2402  
H/M 11

Patent Docket P2534-3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of  
Audrey D. Goddard et al.  
Serial No.: 09/869,566  
Filed: June 29, 2001  
For: IL-1 RELATED POLYPEPTIDES

Group Art Unit: Not yet assigned  
Examiner: Not yet assigned

**CERTIFICATE OF MAILING**  
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on

July 2, 2002

*Tina M. Ingrande*

Tina M. Ingrande

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

**RECEIVED**

Assistant Commissioner of Patents  
Washington, D.C. 20231

JUL 19 2002

Sir:

TECH CENTER 1600/2900

Applicants submit herewith patents, publications or other information (attached hereto and listed on the attached revised Form PTO-1449) of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement is filed in accordance with the provisions of:

**37 CFR §1.97(b)**

- within three months of the filing date of the application other than a continued prosecution application under 37 CFR §1.53(d); **or**
- within three months of the date of entry of the national stage of a PCT application as set forth in 37 CFR§1.491, **or**
- before the mailing of the first Office action on the merits; **or**
- before the mailing of the first Office action after the filing of a request for a continued examination under 37 CFR §1.114.

**37 CFR §1.97(c)**

- by the applicant after the period specified in 37 CFR §1.97(b), but prior to the mailing date of any of a final action under 37 CFR §1.113, or a notice of allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application, and is accompanied by either the fee set forth in 37 CFR §1.17(p) **or** a statement as specified in 37 CFR §1.97(e), as checked below.

**37 CFR §1.97(d)**

- after the period specified in CFR §1.97(c), and is accompanied by the fee set

forth in 37 CFR §1.17(p) and a statement as specified in 37 CFR §1.97(e), as checked below.

[If either of boxes 37 CFR §1.97(c) or 37 CFR §1.97(d) is checked above, the following statement under 37 CFR §1.97(e) may need to be completed.]

- 37 CFR §1.97(e)** Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
- 37 CFR §1.704(d)** Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and the communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of this information disclosure statement. Therefore, in accordance with the provisions of 37 CFR §1.704(d), the filing of this information disclosure statement will not be considered a failure to engage in reasonable efforts to conclude prosecution under 37 CFR §1.704.
- The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p). Any deficiency or overpayment should be charged or credited to this deposit account.

A list of the patent(s) or publication(s) is set forth on the attached revised Form PTO-1449 (Modified).  
**A copy of the items on PTO-1449 is supplied herewith.**

- BLAST results enclosed:

The undersigned also wishes to bring to the attention of the Examiner BLAST results of computerized alignments of the against sequences contained in the nucleotide and protein databases. The BLAST results are provided in paper form and are identified as reference "BLAST Results A-1- A-0" (nucleotide) and "BLAST Results B-1 - B-0" (protein) on the PTO Form 1449. Applicant requests that these references also be considered and that the Form 1449 be initialed to indicate the Examiner's consideration of the references.

A concise explanation of relevance of the items listed on PTO-1449 is:

not given

given for each listed item

Serial No.: 09/869,566  
Filed: June 29, 2001

Page 3

- given for only non-English language listed item(s) [Required]
- in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR §1.97(g), the filing of this information disclosure statement shall not be construed as a representation that a search has been made.

In accordance with 37 CFR §1.97(h), the filing of this information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b).

In the event that the Office determines a fee to be due where none is specifically authorized in this paper, the U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p).

Respectfully submitted,

GENENTECH, INC.

By:   
Craig G. Svoboda  
Reg. No. 39,044  
Telephone No. (650) 225-1489

Date: July 2, 2002



09157

PATENT TRADEMARK OFFICE

115843

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P2534-3	Serial No. 09/869, 599
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Goddard et al.	
				Filing Date 29 Jun 2001	Group

FOREIGN PATENT DOCUMENTS								
Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes	Translation No
	16	WO 00/17363	30.03.00	PCT				
	17	WO 00/24899	04.05.00	PCT				
	18	WO 00/36108 A		PCT				

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

	19	Dinarello et al., "Induction of Interleukin-1 and Interleukin-1 Receptor Antagonist" <u>Seminars in Oncology</u> (Suppl. 9, XP000864695) 24(3):S9-81 - S9-93 (Jun 1997)

RECEIVED

JUL 19 2002

TECH CENTER 1600/2900

Examiner	Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.